Last Updated: November 16, 2026

VEGZELMA Drug Profile

« Back to Dashboard


Summary for Tradename: VEGZELMA
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for VEGZELMA
Recent Clinical Trials for VEGZELMA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Neonc Technologies, Inc.Phase 1/Phase 2
Roswell Park Cancer InstitutePhase 2
National Cancer Institute (NCI)Phase 2

See all VEGZELMA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for VEGZELMA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for VEGZELMA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for VEGZELMA Derived from Patent Text Search

No patents found based on company disclosures

VEGZELMA Market Dynamics and Financial Trajectory

Last updated: November 1, 2026

VEGZELMA, Celltrion’s bevacizumab biosimilar, competes in a mature U.S. market with multiple approved products, declining originator sales, and increasing payer pressure. The product was FDA-approved in September 2022 as bevacizumab-adcd for the same oncology indications as Avastin, including colorectal, lung, brain, ovarian, cervical, and renal cancers. Celltrion does not report VEGZELMA revenue as a separate line item, so product-specific sales, margin, and profitability cannot be verified from public financial statements. The commercial outlook depends on formulary access, hospital contracting, oncology-provider adoption, and price competition with Mvasi, Zirabev, Alymsys, and Avzivi.

What is VEGZELMA and who markets it?

VEGZELMA is the U.S. brand name for bevacizumab-adcd, a monoclonal antibody biosimilar to Genentech/Roche’s Avastin, or bevacizumab. Celltrion developed the product as CT-P16 and markets it through Celltrion USA and regional commercial partners.

Attribute VEGZELMA
Active ingredient Bevacizumab-adcd
Reference product Avastin, bevacizumab
Developer Celltrion
U.S. application Biologics License Application under the 351(k) biosimilar pathway
FDA approval September 27, 2022
Interchangeability Not FDA-designated interchangeable
Primary market Oncology infusion and hospital channels
Dosage form Intravenous infusion
Product type Biosimilar monoclonal antibody
Main competitors Mvasi, Zirabev, Alymsys, Avzivi
U.S. Orange Book listing No. Biologics are tracked primarily through the Purple Book

The FDA found VEGZELMA highly similar to Avastin, with no clinically meaningful differences in safety, purity, or potency. The approval covers the indications for which Avastin was licensed, subject to the scope of the FDA label and applicable patent or regulatory restrictions.[1]

What is the FDA and regulatory status of VEGZELMA?

VEGZELMA is FDA-approved but is not designated interchangeable with Avastin. That distinction affects substitution. A non-interchangeable biosimilar can be prescribed by a physician, but a pharmacist generally cannot substitute it automatically under state pharmacy law without prescriber authorization.

The product is also authorized in Europe under the name Vegzelma. The European Commission granted marketing authorization in 2022 after review by the European Medicines Agency. European uptake depends heavily on national tendering and hospital procurement rather than retail pharmacy substitution.[2]

U.S. regulatory milestones

Date Event
February 26, 2004 Avastin first approved by FDA
February 2016 Twelve-year U.S. reference-product exclusivity for Avastin ended
September 27, 2022 FDA approved VEGZELMA
2022 onward U.S. commercial entry into the bevacizumab biosimilar market
2023-2024 Continued expansion of biosimilar competition and payer contracting

VEGZELMA does not receive a separate period of reference-product exclusivity because it was approved under the abbreviated biosimilar pathway. Its commercial protection comes primarily from manufacturing know-how, supply reliability, contracting, regulatory compliance, and any applicable patent rights.

When does Avastin lose exclusivity, and what does that mean for VEGZELMA?

Avastin’s principal U.S. biologic exclusivity expired in February 2016, while key composition-of-matter patent protection also expired before VEGZELMA entered the market. The commercial barrier is therefore no longer reference-product exclusivity. The relevant competition is between multiple biosimilar manufacturers.

The FDA does not list biologics in the Orange Book in the same manner as small-molecule drugs. Avastin and its biosimilars are included in the Purple Book, which identifies licensed biological products and biosimilarity or interchangeability determinations.[3]

Exclusivity or patent issue Commercial effect on VEGZELMA
Avastin 12-year biologic exclusivity Expired before VEGZELMA approval
Core Avastin patent estate No longer a major barrier to U.S. entry
Orange Book listing Not applicable to the biologic product in the traditional sense
Purple Book status VEGZELMA listed as a biosimilar to Avastin
Interchangeability No automatic substitution status
Product-specific patents May cover manufacturing or formulation details, but do not recreate Avastin exclusivity

How many biosimilars compete with VEGZELMA?

The U.S. bevacizumab market has become structurally competitive. VEGZELMA entered after Amgen’s Mvasi and Pfizer’s Zirabev had already established market access. Alymsys expanded the field, and Avzivi added another approved competitor.

Product Nonproprietary name Sponsor FDA status
Avastin Bevacizumab Genentech/Roche Reference product
Mvasi Bevacizumab-awwb Amgen Biosimilar
Zirabev Bevacizumab-bvzr Pfizer Biosimilar
Alymsys Bevacizumab-maly Amneal/Mabxience Biosimilar
VEGZELMA Bevacizumab-adcd Celltrion Biosimilar
Avzivi Bevacizumab-tnjn Bio-Thera/partners Biosimilar

This market structure limits pricing power. Hospital systems and group purchasing organizations can use competing suppliers to negotiate discounts, secure dual sourcing, and reduce dependence on any single manufacturer.

How does VEGZELMA compare with Mvasi and Zirabev?

Mvasi and Zirabev entered earlier and have had more time to build contracts with oncology practices, hospitals, distributors, and integrated delivery networks. VEGZELMA’s commercial advantage is likely to depend on Celltrion’s ability to offer competitive pricing while maintaining supply consistency.

Factor VEGZELMA Mvasi Zirabev
U.S. market entry Later entrant Early entrant Early entrant
Sponsor scale Large global biosimilar specialist Large biologics manufacturer Large pharmaceutical company
Interchangeability No No No
Main commercial lever Price, supply, contracting Installed account base and scale Procurement reach and portfolio breadth
Primary risk Late-entry share capture Price erosion Price erosion

VEGZELMA is unlikely to win the market through clinical differentiation because biosimilars are expected to deliver comparable clinical outcomes. The principal competitive variables are net price, availability, contracting support, pharmacovigilance, and provider familiarity.

What is the financial trajectory of VEGZELMA?

Celltrion does not separately disclose VEGZELMA revenue in its public annual reports. Reported results combine multiple biosimilar and pharmaceutical products, which prevents a verified product-level revenue calculation.

The financial trajectory can therefore be assessed through market structure and parent-company disclosures rather than a standalone VEGZELMA income statement.

Revenue visibility

Financial metric Publicly available for VEGZELMA? Interpretation
Annual product revenue No separate disclosure identified Cannot verify sales or growth
Gross margin No Depends on transfer pricing, manufacturing cost, and discounts
Net price No public standardized figure Contract prices vary by account
Market share Limited public visibility Claims data and procurement data are required
Celltrion segment revenue Yes Includes multiple products and cannot isolate VEGZELMA
R&D expense Not allocated by product Portfolio-level reporting
Product profitability Not disclosed Requires internal cost and contracting data

Celltrion reported consolidated revenue of approximately KRW 2.18 trillion for 2023, reflecting its broader pharmaceutical and biosimilar portfolio rather than VEGZELMA alone.[4] The company’s biosimilar strategy has emphasized oncology and immunology products, with commercial scale distributed across Remsima, Herzuma, Truxima, and newer products. VEGZELMA contributes to that portfolio but is not individually material enough, or not reported in a manner, that permits a public revenue bridge.

Base-case financial outlook

The base case is moderate revenue growth followed by price compression:

  1. Initial sales increase as additional hospitals and oncology practices add VEGZELMA to formularies.
  2. Net pricing declines as four or more biosimilars compete for the same Avastin volume.
  3. Revenue growth becomes volume-led rather than price-led.
  4. Gross margin depends on manufacturing scale and the extent of discounts required to win tenders.
  5. Profitability improves only if Celltrion achieves sufficient production utilization and avoids excessive channel concessions.

A late entrant can still gain share in a biosimilar market, but the financial return is generally lower than for a first entrant because procurement customers already have approved alternatives.

What market dynamics affect VEGZELMA sales?

Hospital and oncology procurement

Bevacizumab is administered by intravenous infusion in hospitals, ambulatory infusion centers, and oncology clinics. Procurement decisions are usually made by health systems, pharmacy and therapeutics committees, oncology networks, and group purchasing organizations.

The product is not primarily driven by retail pharmacy advertising. Commercial success depends on:

  • Contracted reimbursement and acquisition cost
  • Reliable vial supply
  • Waste reduction and vial-size economics
  • Provider confidence in manufacturing consistency
  • Electronic ordering and billing integration
  • Payer policies for physician-administered drugs
  • Availability of more than one approved supplier

Payer and reimbursement pressure

Biosimilar adoption is affected by reimbursement rules, including buy-and-bill economics under Medicare Part B and commercial payer policies. Providers may select a biosimilar when reimbursement preserves or improves the spread between acquisition cost and payer reimbursement.

The spread can narrow as payers and hospitals obtain larger discounts. This creates a tension for Celltrion: aggressive price reductions may accelerate volume but reduce revenue per vial and margin.

Indication mix

VEGZELMA competes across several oncology indications, but the volume mix is not uniform. High-volume uses include metastatic colorectal cancer, non-small-cell lung cancer, and ovarian cancer. Glioblastoma, cervical cancer, and renal cancer contribute additional demand but may have different treatment patterns and payer controls.

The product has no separate clinical differentiation by indication. Its share must be built across treatment protocols where Avastin and competing bevacizumab biosimilars are accepted.

What is the competitive risk from new bevacizumab biosimilars?

The principal risk is continued price erosion rather than clinical displacement. Every additional approved product increases leverage for purchasers and reduces the probability that one biosimilar can sustain a premium.

Avzivi and any future entrants can pressure VEGZELMA in three ways:

  • Lowering contracted net prices
  • Offering bundled discounts with other oncology products
  • Providing secondary supply that reduces the value of Celltrion’s reliability advantage

Celltrion can offset some of this pressure through portfolio contracting. A supplier with several biosimilars may offer hospitals a broader oncology package, but this strategy can also reduce average net price across the portfolio.

What patents protect VEGZELMA and its manufacturing process?

VEGZELMA is not protected by the Avastin patent estate in the same way as the originator. The commercial patent analysis must distinguish between:

  • Patents covering bevacizumab itself
  • Patents covering VEGZELMA’s cell line, production process, purification, formulation, or analytical methods
  • Patents covering specific methods of treating cancer
  • Patents held by third parties that could create manufacturing or supply risk

Public regulatory approval does not establish freedom to operate in every jurisdiction. Biologic manufacturing patents can remain relevant even after originator composition patents expire. These rights may affect production sites, cell-culture systems, purification steps, or formulation technologies.

No major public U.S. Paragraph IV litigation campaign against VEGZELMA is associated with the product’s FDA approval. Paragraph IV litigation is primarily a Hatch-Waxman mechanism for small-molecule ANDAs. Biosimilar disputes are generally handled through the Biologics Price Competition and Innovation Act patent-exchange framework, often called the patent dance, and through conventional patent litigation.

What generic and biosimilar launch risks exist for VEGZELMA?

VEGZELMA faces biosimilar launch risk rather than conventional generic substitution risk.

Risk Potential effect
Additional bevacizumab biosimilars Lower net price and slower share growth
No interchangeability designation More prescriber and payer friction
Hospital incumbent relationships Higher customer-acquisition cost
Supply disruption Loss of formulary position
Low oncology margins Reduced return on manufacturing investment
Patent or manufacturing disputes Delayed expansion in selected markets
Tender concentration in Europe Rapid volume gains but severe price erosion
Originator contracting response Avastin may retain accounts through rebates or service

What geographic markets are important for VEGZELMA?

The United States and Europe are the most important high-value markets, but their commercial mechanics differ.

The U.S. market rewards contracting, reimbursement execution, and account-level adoption. Europe relies more heavily on national reimbursement decisions, hospital tenders, and country-specific pricing controls. Emerging markets can provide volume, but pricing is typically lower and local registration, distribution, and manufacturing requirements can increase complexity.

Celltrion’s global biosimilar infrastructure gives VEGZELMA access to a broad commercial platform. The product’s financial value will depend on the balance between high-price U.S. sales and lower-price, tender-driven international volume.

What is the likely revenue exposure from Avastin erosion?

Roche reported Avastin sales of approximately CHF 3.0 billion in 2023, down from earlier periods as biosimilar competition expanded.[5] This decline creates a large addressable market, but the revenue is distributed among multiple biosimilars and is reduced by price erosion.

A simple market-sizing framework is:

Variable Impact on VEGZELMA
Avastin addressable sales Sets the gross opportunity
Biosimilar penetration Determines volume available to competitors
VEGZELMA share Determines product volume
Net price after rebates Determines revenue
Manufacturing cost Determines gross margin
Account retention Determines recurring revenue
International tender wins Determines geographic scale

The opportunity is therefore substantial at the category level but limited at the individual-product level. VEGZELMA’s commercial success does not require replacing Avastin entirely. It requires securing durable share against several biosimilar suppliers at an acceptable net price.

Key Takeaways

  • VEGZELMA is Celltrion’s FDA-approved bevacizumab biosimilar, marketed as bevacizumab-adcd.
  • FDA approval occurred on September 27, 2022.
  • The product is not designated interchangeable with Avastin.
  • Avastin’s principal exclusivity barriers expired before VEGZELMA entered the U.S. market.
  • The U.S. market includes Mvasi, Zirabev, Alymsys, VEGZELMA, and Avzivi.
  • Celltrion does not publicly disclose VEGZELMA-specific revenue, pricing, margin, or market share.
  • The product’s financial trajectory is likely volume-driven, with ongoing net-price pressure.
  • Hospital contracting, supply reliability, payer reimbursement, and oncology-network access are more important than clinical differentiation.
  • No major public Paragraph IV litigation campaign is central to VEGZELMA’s U.S. launch.
  • Manufacturing patents, process know-how, and geographic regulatory approvals remain relevant to long-term supply and market access.

FAQs

Is VEGZELMA interchangeable with Avastin?

No. FDA approved VEGZELMA as a biosimilar to Avastin but did not designate it interchangeable. Substitution rules depend on state law and payer or prescriber policy.

Does VEGZELMA have an Orange Book patent listing?

No conventional Orange Book listing applies. Biologic reference products and biosimilars are primarily tracked through the FDA Purple Book.

Who owns VEGZELMA?

Celltrion developed and markets VEGZELMA. Regional commercialization may involve local affiliates or distribution partners.

Is VEGZELMA cheaper than Avastin?

Biosimilars generally compete through lower net prices, but actual discounts vary by hospital, payer, distributor, and purchasing contract. A single public price does not represent the market-wide net price.

Can VEGZELMA replace Avastin in all approved cancer indications?

VEGZELMA’s FDA label covers the Avastin indications identified in its approval. Actual use depends on physician judgment, payer policy, treatment guidelines, and institutional formulary status.

References

  1. U.S. Food and Drug Administration. (2022, September 27). FDA approves biosimilar to Avastin. https://www.fda.gov
  2. European Medicines Agency. (2022). Vegzelma: EPAR. https://www.ema.europa.eu
  3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
  4. Celltrion, Inc. (2024). Annual report 2023. https://www.celltrion.com
  5. Roche Holding AG. (2024). Annual report 2023. https://www.roche.com/annual-report

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.